No black box warning on record for Xtandi

As of the latest FDA labeling reviewed, Xtandi (ENZALUTAMIDE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Xtandi medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Seizure occurred in 0.6% of patients receiving XTANDI. In patients with predisposing factors, seizures were reported in 2.2% of patients. Permanently discontinue XTANDI in patients who develop a seizure during treatment. ( 5.1 ) • Posterior reversible encephalopathy syndrome (PRES): Discontinue XTANDI. ( 5.2 ) • Hypersensitivity: Discontinue XTANDI. ( 5.3 ) • Ischemic

No black box warning on record for Xtandi

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Seizure occurred in 0.6% of patients receiving XTANDI. In patients with predisposing factors, seizures were reported in 2.2% of patients. Permanently discontinue XTANDI in patients who develop a seizure during treatment. ( 5.1 ) • Posterior reversible encephalopathy syndrome (PRES): Discontinue XTANDI. ( 5.2 ) • Hypersensitivity: Discontinue XTANDI. ( 5.3 ) • Ischemic

Xtandi Black Box Warning

No black box warning on record for Xtandi

Other warnings & precautions

Xtandi Black Box Warning

No black box warning on record for Xtandi

Other warnings & precautions